ABBV•benzinga•
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now
Summary
Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 22, 2025 by benzinga